HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Consumers Challenge DMAA Safety After DOD Bans Products

This article was originally published in The Tan Sheet

Executive Summary

Complaints against GNC Holdings Inc., manufacturer Cellucor Sports Nutrition and Woodbolt Distribution and against USPLabs rely on DOD’s decision to ban sales of the product at military exchanges and moves by Canadian regulators to support their arguments.

You may also be interested in...



Class Action Claims Often Follow Regulatory Action, Industry Litigation

FDA warning letters, FTC consent orders, Lanham Act litigation and National Advertising Division reviews all provide fodder for attorneys looking to bring consumer product lawsuits. While some case settlements come with large monetary payments, injunctive components also are common and often costly.

U.S. Military Investigates Supplement Ingredient DMAA, Bans Sales

DoD suspends DMAA sales at military stores after regulators in Canada and New Zealand restricted access and as some U.S. firms change how they market and label the ingredient. These moves and the potential for an FDA review could lead to enforcement against DMAA similar to the 2004 ban against ephedra’s use in supplements.

New Dietary Ingredient Notification Draft Guidance Must Be Withdrawn – CRN and CHPA

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

RS124719

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel